US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Twist Bioscience Corporation - Common Stock
(NQ:
TWST
)
152.78
-20.67 (-11.92%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Twist Bioscience Corporation - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021
April 22, 2021
From
Twist Bioscience Corporation
Via
Business Wire
Twist Bioscience to Expand Oregon Lease, Supporting Future Growth
April 16, 2021
From
Twist Bioscience Corporation
Via
Business Wire
Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities
April 14, 2021
From
Twist Bioscience Corporation
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2021
↗
April 12, 2021
Upgrades For Eni SpA (NYSE:E), Credit Suisse upgraded the previous rating of Underperform to Neutral. For the fourth quarter, Eni had an EPS of $0.02, compared to year-ago...
Via
Benzinga
Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software
April 12, 2021
From
Twist Bioscience
Via
Business Wire
Ginkgo Bioworks, Which Prints DNA And Creates Genetically Modified Food, Exploring SPAC Deal: Report
↗
April 09, 2021
One of the largest SPACs seeking a target could be nearing a $20 billion deal to bring one of the largest privately-held biotechnology companies public. The SPAC Rumor: Bloomberg...
Via
Benzinga
AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests
April 07, 2021
From
Twist Bioscience Corporation
Via
Business Wire
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
April 07, 2021
From
Twist Bioscience Corporation
Via
Business Wire
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
